The sbPCI platform eliminates T-cell and CD3+CD8+ isolation steps and enables rapid optimization of molecular formats to accelerate CAGT immunotherapy innovation. The molecular configuration of co-stimulatory molecules presented to PBMCs can be easily optimized using the sbPCI system. Change in molecular formats affect T cell expansion and phenotypes.
StimulusBio’s Chief Executive Officer, Mimi Healy, PhD, joined an esteemed panel of scientific and industry leaders for the session “Boost Your Biotech: Non-Dilutive Funding for Life Science Companies” at the Texas Life Science Forum.
Dexamethasone resistant cell therapy is achievable and scalable for patients undergoing long-term immunosuppressive treatment. The treated cells expressed similar levels of cytolytic enzymes as untreated cultures and expanded a majority of CD3+CD8+ cells. The results support the viability of manufacturing potent corticosteroid-resistant therapies for patients.
We discussed how StimulusBio overcomes operational and commercialization aspects, leveraging Stacie’s unique journey across marketing, chemical engineering, and her experience with successful biotech exits. Experience from previous startups profoundly the transition from incubation to market. We explored the critical stages of startup growth, emphasizing the importance of marketing, storytelling, team building, and experience-based advice. Stacie also shared her insights into the emerging trends in the biotech industry, particularly in Houston’s growing biotech ecosystem, and the importance of balancing innovation with practical business needs.
